Home › Atopic Dermatitis (Eczema) › NCT06244212

Topical Treatment for Atopic Dermatitis

Who can join

Ages 9 and older · All sexes

Inclusion Criteria:

* Diagnosis of skin dermatitis
* Age \> 9
* Ability to return for a one-week clinical studies follow-up
* Patients who are candidates for treatment with 0.1% triamcinolone ointment (even if they weren't in the study)
* Adult or pediatric patients with active dermatitis who receive dermatologic care at Atrium Health Wake Forest Baptist, Department of Dermatology.

Exclusion Criteria:

* Patients without the diagnosis of skin dermatitis
* Inability to return for a one week follow up appointment
* Body Surface Area (BSA) affected \<2%

About the study

Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. Non-adherence is of importance as it is a significant cause of treatment failure, resulting in worse quality of life, worse health outcomes, and increased insurance costs.

What is being tested

• Demonstration of applying triamcinolone cream (other)
• Mobile App Use (behavioral)
• Standard of Care (other)

Sponsor: Wake Forest University Health Sciences · Participants: 30 · Started: Sep 19, 2024

Contact the study team

• Irma Richardson, MHA · Phone: 336.716.2903

Official record on ClinicalTrials.gov — NCT06244212

Locations in the U.S.

Conditions

• Atopic Dermatitis (Eczema)

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.